Targeting the interleukin-23/17 axis in axial spondyloarthritis
A Paine, CT Ritchlin - Current opinion in rheumatology, 2016 - journals.lww.com
A Paine, CT Ritchlin
Current opinion in rheumatology, 2016•journals.lww.com… This article highlights and emphasizes how new knowledge of mechanisms linked to the
interleukin-23 (IL-23)/IL-17 pathway is relevant to the pathophysiology of axial spondyloarthritis
(axSpA) and demonstrates how molecules in IL-23/IL-17 pathway provide novel therapeutic
targets for axSpA patients. … Current studies provide a tantalizing glimpse of the relationship
between gut dysbiosis and axial inflammation, but we require confirmatory data from both
preclinical studies and human tissues to confirm the specifics of the proposed gut-axial disease …
interleukin-23 (IL-23)/IL-17 pathway is relevant to the pathophysiology of axial spondyloarthritis
(axSpA) and demonstrates how molecules in IL-23/IL-17 pathway provide novel therapeutic
targets for axSpA patients. … Current studies provide a tantalizing glimpse of the relationship
between gut dysbiosis and axial inflammation, but we require confirmatory data from both
preclinical studies and human tissues to confirm the specifics of the proposed gut-axial disease …
Summary
Recent studies further establish the central position of the IL-23/IL-17 pathway in the pathogenesis of axSpA. Targeting the IL-23/IL-17 pathway appears to be a safe and effective strategy for treatment of axSpA patients.
Lippincott Williams & Wilkins以上显示的是最相近的搜索结果。 查看全部搜索结果